Literature DB >> 14970024

Correlation of angiographic circulation time and cerebrovascular reserve by acetazolamide-challenged single photon emission CT.

Shiro Yamamoto1, Manabu Watanabe, Toshihiko Uematsu, Kenichiro Takasawa, Masaru Nukata, Naokazu Kinoshita.   

Abstract

BACKGROUND AND
PURPOSE: Although cerebral circulation time (CCT) is one of the main parameters in cerebral blood flow measurements, its clinical significance is controversial. To assess the importance of CCT by using a nondiffusible indicator, we studied the relationship between angiographic CCT and cerebrovascular reserve.
METHODS: Twenty-eight patients, each with a unilateral occlusive lesion in the internal carotid artery or middle cerebral artery, were examined. To assess the CCT, the regional arteriocapillary circulation time (rACCT) was measured by angiography and the ratio of the value on the occlusive side to the value on the contralateral side was calculated as the rACCT ratio. To estimate the cerebrovascular reserve, acetazolamide-challenged single photon emission CT was used. Patients with a decreased cerebrovascular reserve were defined as the "poor reserve" group, and those without a decrease were defined as the "normal reserve" group. The ratio of the radioactivity count on the occlusive side to the count on the contralateral side was calculated as the asymmetry index, and the proportion of the acetazolamide-challenged asymmetry index to the baseline asymmetry index was defined as the regional reactivity index.
RESULTS: The rACCT ratio in the poor reserve group (n = 19) was significantly (P <.001) larger than that in the normal reserve group (n = 9), and a significant correlation (r = -0.83, P <.01) was found between the rACCT ratio and the regional reactivity index.
CONCLUSION: The angiographic CCT and the cerebral vasoreactivity to acetazolamide on single photon emission CT were well correlated, suggesting that measurement of the CCT by using a nondiffusible indicator could be used as an index of cerebrovascular reserve.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14970024      PMCID: PMC7974592     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  28 in total

1.  Quantitative assessment of the ischemic brain by means of perfusion-related parameters derived from perfusion CT.

Authors:  M Koenig; M Kraus; C Theek; E Klotz; W Gehlen; L Heuser
Journal:  Stroke       Date:  2001-02       Impact factor: 7.914

2.  Effect of intraarterial papaverine on cerebral circulation time.

Authors:  J M Milburn; C J Moran; D T Cross; M N Diringer; T K Pilgram; R G Dacey
Journal:  AJNR Am J Neuroradiol       Date:  1997 Jun-Jul       Impact factor: 3.825

3.  Normal cerebral circulation time as determined by carotid angiography with sodium and methylglucamine diatrizoate (Urografin).

Authors:  T Greitz
Journal:  Acta Radiol Diagn (Stockh)       Date:  1968-07

4.  The ischemic penumbra: operationally defined by diffusion and perfusion MRI.

Authors:  G Schlaug; A Benfield; A E Baird; B Siewert; K O Lövblad; R A Parker; R R Edelman; S Warach
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

5.  Normal values of cerebrovascular reserve capacity after stimulation with acetazolamide measured by xenon 133 single-photon emission CT.

Authors:  G Leinsinger; A Piepgras; K Einhäupl; P Schmiedek; C M Kirsch
Journal:  AJNR Am J Neuroradiol       Date:  1994-08       Impact factor: 3.825

6.  [Circulation time determined by carotid angiography in patients with chronic internal carotid artery occlusion: comparison with cerebral blood flow and oxygen metabolism measured by PET].

Authors:  H Ito; A Inugami; F Shishido; T Okudera; T Ogawa; J Hatazawa; H Fujita; E Shimosegawa; I Kanno; H Fukuda
Journal:  Kaku Igaku       Date:  1994-10

Review 7.  Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status.

Authors:  Peter D Schellinger; Jochen B Fiebach; Werner Hacke
Journal:  Stroke       Date:  2003-02       Impact factor: 7.914

8.  Cerebrovascular reactivity to acetazolamide in carotid artery disease. Enhancement of side-to-side CBF asymmetry indicates critically reduced perfusion pressure.

Authors:  T Schroeder
Journal:  Neurol Res       Date:  1986-12       Impact factor: 2.448

9.  Acute effects of acetazolamide on cerebral blood flow in man.

Authors:  A Hauge; G Nicolaysen; M Thoresen
Journal:  Acta Physiol Scand       Date:  1983-02

10.  99mTc-HMPAO-SPECT with acetazolamide challenge to detect hemodynamic compromise in occlusive cerebrovascular disease.

Authors:  J Knop; A Thie; C Fuchs; G Siepmann; H Zeumer
Journal:  Stroke       Date:  1992-12       Impact factor: 7.914

View more
  10 in total

1.  Monitoring peri-therapeutic cerebral circulation time: a feasibility study using color-coded quantitative DSA in patients with steno-occlusive arterial disease.

Authors:  C J Lin; S C Hung; W Y Guo; F C Chang; C B Luo; J Beilner; M Kowarschik; W F Chu; C Y Chang
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-12       Impact factor: 3.825

2.  Which CT perfusion parameter best reflects cerebrovascular reserve?: correlation of acetazolamide-challenged CT perfusion with single-photon emission CT in Moyamoya patients.

Authors:  N-J Rim; H S Kim; Y S Shin; S Y Kim
Journal:  AJNR Am J Neuroradiol       Date:  2008-07-10       Impact factor: 3.825

3.  Quantification of cerebrovascular reactivity by blood oxygen level-dependent MR imaging and correlation with conventional angiography in patients with Moyamoya disease.

Authors:  C Heyn; J Poublanc; A Crawley; D Mandell; J S Han; M Tymianski; K terBrugge; J A Fisher; D J Mikulis
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-14       Impact factor: 3.825

4.  Relationships between hypercarbic reactivity, cerebral blood flow, and arterial circulation times in patients with moyamoya disease.

Authors:  Manus J Donahue; Michael Ayad; Ryan Moore; Matthias van Osch; Robert Singer; Paul Clemmons; Megan Strother
Journal:  J Magn Reson Imaging       Date:  2013-02-25       Impact factor: 4.813

5.  Patient selection for revascularization procedures in adult Moyamoya disease based on dynamic perfusion computerized tomography with acetazolamide challenge (PCTA).

Authors:  Norberto Andaluz; Ondrej Choutka; Achala Vagal; Rhonda Strunk; Mario Zuccarello
Journal:  Neurosurg Rev       Date:  2010-02-06       Impact factor: 3.042

6.  Cerebral Circulation Time After Thrombectomy: A Potential Predictor of Outcome After Recanalization in Acute Stroke.

Authors:  Jia-Qi Wang; Ying-Jia Wang; Jin Qiu; Wei Li; Xian-Hui Sun; Yong-Gang Zhao; Xin Liu; Zi-Ai Zhao; Liang Liu; Thanh N Nguyen; Hui-Sheng Chen
Journal:  J Am Heart Assoc       Date:  2022-05-27       Impact factor: 6.106

7.  Correlative assessment of cerebral blood flow obtained with perfusion CT and positron emission tomography in symptomatic stenotic carotid disease.

Authors:  Sotirios Bisdas; Ole Nemitz; Georg Berding; Karin Weissenborn; Bjoern Ahl; Hartmut Becker; Frank Donnerstag
Journal:  Eur Radiol       Date:  2006-04-01       Impact factor: 5.315

8.  Unilateral hemispheric proliferation of ivy sign on fluid-attenuated inversion recovery images in moyamoya disease correlates highly with ipsilateral hemispheric decrease of cerebrovascular reserve.

Authors:  M Kawashima; T Noguchi; Y Takase; T Ootsuka; N Kido; T Matsushima
Journal:  AJNR Am J Neuroradiol       Date:  2009-08-27       Impact factor: 3.825

9.  Quantitative cerebrovascular reserve measured by acetazolamide-challenged dynamic CT perfusion in ischemic adult Moyamoya disease: initial experience with angiographic correlation.

Authors:  K H Kang; H S Kim; S Y Kim
Journal:  AJNR Am J Neuroradiol       Date:  2008-05-22       Impact factor: 3.825

10.  Prolonged Cerebral Circulation Time Is the Best Parameter for Predicting Vasospasm during Initial CT Perfusion in Subarachnoid Hemorrhagic Patients.

Authors:  Chun Fu Lin; Sanford P C Hsu; Chung Jung Lin; Wan Yuo Guo; Chih Hsiang Liao; Wei Fa Chu; Sheng Che Hung; Yang Shin Shih; Yen Tzu Lin
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.